会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Ether muscarinic antagonists
    • 醚类毒蕈碱拮抗剂
    • US5977138A
    • 1999-11-02
    • US910616
    • 1997-08-13
    • Yuguang WangWei K. ChangSundeep DugarSamuel Chackalamannil
    • Yuguang WangWei K. ChangSundeep DugarSamuel Chackalamannil
    • A61K45/06C07D211/46C07D211/96C07D405/12C07D405/14C07D409/14A61K31/445C07D401/04
    • C07D405/12A61K45/06C07D211/46C07D211/96C07D405/14C07D409/14
    • 1,4 Di-substituted piperidine muscarinic antagonists of formula I ##STR1## or an isomer, pharmaceutically acceptable salt, ester or solvate thereof, whereinX is a bond, --O--, --S--, --SO--, --SO.sub.2 --, --CO--, --C(OR.sup.7).sub.2 --, --CH.sub.2 --O--, --O-- CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --, --CH(C.sub.1 -C.sub.6 alkyl)-, --C(C.sub.1 -C.sub.6 alkyl).sub.2 --, --CONR.sup.17 --, --NR.sup.17 CO--, --O--C(O)NR.sup.17 --, --NR.sup.17 C(O)--O--, --SO.sub.2 NR.sup.17 -- or --NR.sup.17 SO.sub.2 --;R is cycloalkyl, optionally substituted phenyl or optionally substituted pyridyl;R.sup.2 is H, alkyl, optionally substituted cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted piperidinyl; and the remaining variables are as defined in the specification, are disclosed. Compounds of formula I are useful for treating cognitive disorders such as Alzheimer's disease. Also disclosed are pharmaceutical compositions, methods of preparation and combinations of compounds of formula I with ACh'ase inhibitors.
    • 1,4-二取代的式I的哌啶毒蕈碱拮抗剂或其异构体,药学上可接受的盐,酯或溶剂化物,其中X是键,-O - , - S - , - SO - , - SO 2 - , - ,-C(OR 7)2 - , - CH 2 -O - , - CH 2 - , - CH = CH - , - CH 2 - , - CH(C 1 -C 6烷基) - , - CONR 17 - , - NR 17 CO - , - OC(O)NR 17 - , - NR 17 C(O)-O-,-SO 2 NR 17 - 或-NR 17 SO 2 - R是环烷基,任选取代的苯基或任选取代的吡啶基; R2是H,烷基,任选取代的环烷基,环烯基,叔丁氧羰基或任选取代的哌啶基; 并且其余变量如说明书中所定义。 式I化合物可用于治疗认知障碍如阿尔茨海默病。 还公开了药物组合物,制备方法和式I化合物与ACh酶抑制剂的组合。
    • 8. 发明授权
    • Synthesis of .alpha.-substituted-aryl ethylamines
    • α-取代的芳基乙胺的合成
    • US5530125A
    • 1996-06-25
    • US290894
    • 1994-08-19
    • Joel G. BergerWei K. ChangJoseph A. KozlowskiGuowei Zhou
    • Joel G. BergerWei K. ChangJoseph A. KozlowskiGuowei Zhou
    • C07D217/24A61K31/55A61P25/00A61P25/18B01J31/24C07B61/00C07C231/12C07D209/34C07D213/56C07D223/16C07D225/06C07D233/64C07D277/30C07D307/54C07D333/24C07D491/056
    • C07D223/16
    • A novel process for the preparation of .alpha.-substituted arylacetamides wherein the substituent is an aromatic group or a 1-alkenyl or 1-cycloalkenyl group and wherein the nitrogen atom carries no hydrogen atoms comprises the reaction of an arylacetamide having one or two hydrogen atoms on the .alpha.-carbon atom, wherein the nitrogen atom carries no hydrogen atoms, with a strong base in an inert aprotic organic solvent, followed by reaction with a zerovalent transition metal catalyst and then with a compound of the formula R.sup.4 --X, wherein R.sup.4 is selected from aromatic groups, 1-alkenyl groups and 1-cycloalkenyl groups and X is a particular leaving group, especially a triflate group. The .alpha.-substituted arylacetamides are useful as intermediates in the preparation (by reduction) of .alpha.-substituted arylethylamines, e.g., 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines, having pharmacological activity. Certain benzazepines wherein the 1-substituent R.sup.4 is 1-(1-cycloalkenyl) are novel.
    • PCT No.PCT / US93 / 01425 Sec。 371日期:1994年8月19日 102(e)日期1994年8月19日PCT提交1993年2月23日PCT公布。 公开号WO93 / 16997 日期:1993年9月2日。一种制备α-取代芳基乙酰胺的新方法,其中取代基是芳基或1-烯基或1-环烯基,其中氮原子不携带氢原子包括芳基乙酰胺 在α-碳原子上具有一个或两个氢原子,其中氮原子不携带氢原子,在惰性非质子有机溶剂中具有强碱,随后与零价过渡金属催化剂反应,然后与式 R4-X,其中R4选自芳族基团,1-烯基和1-环烯基,X是特定的离去基团,特别是三氟甲磺酸酯基团。 α-取代的芳基乙酰胺可用作制备(通过还原)具有药理活性的α-取代的芳基乙胺,例如1-取代-2,3,4,5-四氢-1H-3-苯并氮杂的中间体。 其中1-取代基R4是1-(1-环烯基)的某些苯并氮杂是新的。
    • 10. 发明授权
    • Substituted benzazepines, their preparation and pharmaceutical
compositions containing them
    • 取代苯并吖庚因,其制剂和含有它们的药物组合物
    • US5015639A
    • 1991-05-14
    • US322801
    • 1989-03-13
    • Joel G. BergerWei K. ChangMarjorie Peters
    • Joel G. BergerWei K. ChangMarjorie Peters
    • C07D223/16C07D223/32C07D401/04C07D403/04C07D521/00
    • C07D223/16C07D223/32C07D231/12C07D233/56C07D249/08C07D401/04C07D403/04
    • Disclosed herein are novel 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines of the general formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are specified substituents.R.sup.1 is preferably --X.sup.6, --CHR.sup.7 R.sup.8, cycloalkyl, cycloalkenyl, ##STR2## or pyrrolyl where m is 1, R.sup.6 represents .dbd.H, phenyl, substituted phenyl, aralkyl, alkyl, cycloalkyl, haloalkyl or alkoxyalkyl, R.sup.7 represents H or alkyl preferably H, R.sup.8 represents cycloalkyl, cycloalkenyl, haloalkyl, alkoxyalkyl, alkenyl or alkynyl and R.sup.9 represents alkyl, aloxy or alkoxyalkyl.R.sup.2 preferably represents --H and R.sup.3 --CH.sub.3, and R.sup.4 is preferably halogen and R.sup.5 is preferably OH, OCO.R.sup.9 or --O(CR.sup.7).sub.2.OCO.R.sup.13 where R.sup.7 represents hydrogen, R.sup.9 is as defined above and R.sup.13 represents alkyl. The compounds of the formula I are indicated as being useful in the treatment of psychoses, depression and pain. Also disclosed are process for the preparation of the novel compounds as well as pharmaceutical compositions comprising them.
    • 本文公开了通式I的新的1-取代-2,3,4,5-四氢-1H-3-苯并吖庚因:其中R 1,R 2,R 3,R 4和R 5是指定的取代基。 R1优选为-X6,-CHR7R8,环烷基,环烯基,或吡咯基,其中m为1,R6表示= H,苯基,取代的苯基,芳烷基,烷基,环烷基,卤代烷基或烷氧基烷基,R7表示H或烷基, R8表示环烷基,环烯基,卤代烷基,烷氧基烷基,烯基或炔基,R9代表烷基,氧基或烷氧基烷基。 R2优选表示-H和R3-CH3,R4优选为卤素,R5优选为OH,OCO.R9或-O(CR7)2.OCO.R13,其中R7表示氢,R9如上所定义,R13表示烷基。 式I化合物表示可用于治疗精神病,抑郁症和疼痛。 还公开了制备新化合物的方法以及包含它们的药物组合物。